How should health systems decide whether the benefits of new medicines are worth the costs? Health economic thresholds are increasingly used to guide reimbursement decisions, yet the basis for these thresholds and their real-world consequences remain the subject of intense debate...
We aim to contribute to affordable, equitable and sustainable access to safe, effective and quality essential medicines in Austria, Europe and globally.
GÖG-Colloquium (20 January 2026): Health Economic Thresholds and Reimbursement Decisions for Medicines
Biosimilar policies: New Evidence from 32 European countries
Experts of the Pharmacoeconomics Department are leading a three-year EU4Health project “Capacity building to support the uptake of biosimilars in a multistakeholder approach” ( AUGMENT Biosimilars). The first year of the AUGMENT Biosimilars project focused on a comprehensive...
Updated PPRI Pharma Brief Germany published
The 2025 edition of PPRI Pharma Brief on Germany provides a comprehensive and up-to-date overview of the German pharmaceutical system, highlighting recent policy developments. This edition is complemented by a detailed flowchart and a list of key stakeholders. PPRI Pharma Briefa...